ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1663773
This article is part of the Research TopicResearch and Innovation Approaches to Personalized Pharmacotherapies for Respiratory DiseasesView all 6 articles
Association Between Acetaminophen Use and 30-Day Mortality in Critically Ill Patients with Pulmonary Embolism: A Retrospective Cohort Study Using the MIMIC-IV Database
Provisionally accepted- 1Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China
- 2Fujian Provincial Hospital, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: Pulmonary embolism (PE) has high mortality rates among critically ill patients. While acetaminophen shows potential therapeutic effects in critical illness, its impact on ICU patients with PE remains unclear. This study evaluated the association between acetaminophen use and 30-day mortality in ICU patients with PE. Patients and methods: A retrospective cohort study was conducted using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Adult patients admitted to the ICU with confirmed PE between 2008 and 2022 were included. The primary exposure was acetaminophen use during the ICU stay, and the primary outcome was 30-day all-cause mortality. To control for confounding factors, propensity score matching (PSM) was applied, along with inverse probability weighting, propensity score adjustment, and E-value analysis to assess result robustness. Causal mediation analysis was performed to evaluate the mediating role of body temperature. Results: Among 1,983 eligible patients, 1,355 received acetaminophen and 628 did not. After propensity score matching (599 pairs), acetaminophen use was associated with a 31% reduction in 30-day mortality risk (HR 0.69, 95% CI: 0.56–0.85, P=0.001). This protective effect was more pronounced in patients requiring mechanical ventilation (HR 0.53, 95% CI: 0.34–0.82) and vasopressor support (HR 0.52, 95% CI: 0.32–0.83). Enhanced benefits were also observed in younger patients (<65 years, HR 0.52, 95% CI: 0.31–0.85). Multiple sensitivity analyses yielded consistent results, with E-values ranging from 2.03 to 2.26, suggesting robust resistance to unmeasured confounding. Causal mediation analysis revealed that 54.2% (95% CI: 25.6% to 187.5%, P=0.014) of acetaminophen's apparent protective effect was mediated through body temperature regulation during hospitalization. Conclusion: Acetaminophen use was associated with reduced 30-day mortality in critically ill patients with PE, with temperature control appearing to play a potential mediating role. These preliminary findings provide hypothesis-generating evidence that warrants validation in prospective randomized controlled trials before clinical implementation.
Keywords: Acetaminophen, Pulmonary Embolism, Intensive Care Unit, 30-day mortality, Propensity score matching, Causal mediation analysis
Received: 10 Jul 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Qiu, Lin, Tu, Jiang, Shang, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xincai Wang, Fujian Provincial Hospital, Fuzhou, China
Long Huang, Fujian Provincial Hospital, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.